Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03169361 · FLOW

Participant flow

NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" · Source last updated 2023-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    The usual adult dosage for oral administration was 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle was repeated for 6 cycles. The dose might be reduced appropriately according to the patient's condition. Participants received interventions as part of routine medical care.
    id
    FG000
    title
    Ixazomib 4 mg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        32
      type
      Protocol Violation
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        774
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        742
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants with a historical diagnosis of relapsed/refractory multiple myeloma were enrolled. Participants received ixazomib as part of a routine medical care.
recruitment Details
Participants took part in the survey at 316 investigative sites in Japan, from 24 May 2017 to 8 March 2022.
Complete source fields
groups
  1. description
    The usual adult dosage for oral administration was 4 mg as ixazomib, in the fasting state, once a day, once a week for 3 weeks (Days 1, 8, and 15), with a 13-day washout period (Days 16 through 28). This 4-week cycle was repeated for 6 cycles. The dose might be reduced appropriately according to the patient's condition. Participants received interventions as part of routine medical care.
    id
    FG000
    title
    Ixazomib 4 mg
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        32
      type
      Protocol Violation
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        774
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        742
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        32
      type
      NOT COMPLETED
    title
    Overall Study
pre Assignment Details
Participants with a historical diagnosis of relapsed/refractory multiple myeloma were enrolled. Participants received ixazomib as part of a routine medical care.
recruitment Details
Participants took part in the survey at 316 investigative sites in Japan, from 24 May 2017 to 8 March 2022.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice